Clinical Trial Update: Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on panobinostat (LBH589) for prevention of acute graft-versus-host disease (aGVHD) after transplant; study completed with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• LBH589 (panobinostat)
• Panobinostat (Panobinostat)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Graft Versus Host Disease, GVHD | Phase 2 | Status: COMPLETED | Results posted: 2020-01-03